Synthesis, biological evaluation, and molecular docking studies of novel N-substituted piperazine-tethered thiophene-3-carboxamide selenides as potent antiproliferative agents with EGFR kinase inhibitory activity

被引:1
作者
Makhal, Priyanka N. [1 ]
Dayare, Lahu N. [1 ]
Chilvery, Shrilekha [2 ]
Devi, Priyanka [2 ]
Shaikh, Arbaz Sujat [1 ]
Sharma, Anamika [2 ]
Negi, Aakansha [1 ]
Godugu, Chandraiah [2 ]
Kaki, Venkata Rao [1 ]
机构
[1] Natl Inst Pharmaceut Educ & Res NIPER, Dept Chem Sci, Hyderabad 500037, India
[2] Natl Inst Pharmaceut Educ & Res NIPER, Dept Regulatory Toxicol, Hyderabad 500037, India
关键词
Organoselenium; Thiophene; EGFR kinase inhibition; Antiproliferative; Apoptosis; DERIVATIVES; DESIGN; DISCOVERY; APOPTOSIS;
D O I
10.1016/j.bioorg.2024.107677
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
In the context of structural investigation and optimization of various potential EGFR inhibitors, a novel series of asymmetrical piperazine-tethered trisubstituted thiophene-3-carboxamide selenide derivatives were synthesized and evaluated for their antiproliferative potential against selected human cancer cell lines. These derivatives, built based on a previously identified hit molecule, were synthesized via multiple-step reactions, including optimization of the C-Se cross-coupling reaction. Two compounds, 17i and 18i, displayed significant cytotoxicity (IC50 value: 4.82 +/- 0.80 mu M and 1.43 +/- 0.08 mu M) against HCT116 and A549 cancer cell lines, respectively. Quantitative analysis of apoptotic stages using Annexin V-FITC/PI double staining validated their apoptotic potential. Further, compound 18i demonstrated a remarkable inhibition of EGFR kinase, with an IC50 concentration of 42.3 nM. The lead compound 18i, with remarkable in vitro cytotoxicity, apoptosis induction capability, and EGFR inhibition, emerges as a promising candidate for anticancer therapy.
引用
收藏
页数:22
相关论文
共 28 条
[1]  
Akl Laila, 2022, Eur J Med Chem, V243, P114704, DOI 10.1016/j.ejmech.2022.114704
[2]   Novel Synthesis of 5-Amino-3-bromo-1-(tert-butyl)-1H-pyrazole-4-carbonitrile: A Versatile Intermediate for the Preparation of 5-Amino-3-aryl-1-(tert-butyl)-1H-pyrazole-4-carboxamides [J].
Bobko, Mark A. ;
Kaura, Arun C. ;
Evans, Karen A. ;
Su, Dai-Shi .
ORGANIC LETTERS, 2012, 14 (15) :3906-3908
[3]  
Chazotte Brad, 2011, Cold Spring Harb Protoc, V2011, DOI 10.1101/pdb.prot5556
[4]  
Choi JA, 2001, INT J ONCOL, V19, P837
[5]   Drug therapy: EGFR antagonists in cancer treatment [J].
Ciardiello, Fortunato ;
Tortora, Giampaolo .
NEW ENGLAND JOURNAL OF MEDICINE, 2008, 358 (11) :1160-1174
[6]   Synthesis and investigation of novel 6-(1,2,3-triazol-4-yl)-4-aminoquinazolin derivatives possessing hydroxamic acid moiety for cancer therapy [J].
Ding, Chao ;
Chen, Shaopeng ;
Zhang, Cunlong ;
Hu, Guangnan ;
Zhang, Wei ;
Li, Lulu ;
Chen, Yu Zong ;
Tan, Chunyan ;
Jiang, Yuyang .
BIOORGANIC & MEDICINAL CHEMISTRY, 2017, 25 (01) :27-37
[7]   Novel intramolecular π-π-interaction in a BODIPY system by oxidation of a single selenium center: geometrical stamping and spectroscopic and spectrometric distinctions [J].
Kim, Youngsam ;
Jun, Taehong ;
Mulay, Sandip V. ;
Manjare, Sudesh T. ;
Kwak, Jinseong ;
Lee, Yunho ;
Churchill, David G. .
DALTON TRANSACTIONS, 2017, 46 (12) :4111-4117
[8]   2,4-Disubstituted quinazolines targeting breast cancer cells via EGFR-PI3K [J].
Li, Er-dong ;
Lin, Qiao ;
Meng, Ya-qi ;
Zhang, Lu-ye ;
Song, Pan-pan ;
Li, Na ;
Xin, Jing-chao ;
Yang, Peng ;
Bao, Chong-nan ;
Zhang, Dan-qing ;
Zhang, Yang ;
Wang, Ji-kuan ;
Zhang, Qiu-rong ;
Liu, Hong-min .
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2019, 172 :36-47
[9]  
Li Z., 2008, Patent No. [CN101274908A, 101274908]
[10]   Selenocystine-induced cell apoptosis and S-phase arrest inhibit human triple-negative breast cancer cell proliferation [J].
Long, Meijun ;
Wu, Juekun ;
Hao, Junwen ;
Liu, Wei ;
Tang, Yong ;
Li, Xi ;
Su, Hang ;
Qiu, Wanshou .
IN VITRO CELLULAR & DEVELOPMENTAL BIOLOGY-ANIMAL, 2015, 51 (10) :1077-1084